Publication | Open Access
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
127
Citations
21
References
2018
Year
Novartis Pharmaceuticals Corporation.
| Year | Citations | |
|---|---|---|
Page 1
Page 1